NCT02392494View on ClinicalTrials.gov

Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 28, 2015

Primary Completion Date

August 10, 2015

Study Completion Date

August 10, 2015

Conditions
Hepatitis C
Interventions
DRUG

MK-1075

MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02392494 - Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002) | Biotech Hunter | Biotech Hunter